239 related articles for article (PubMed ID: 26676908)
1. Efficacy and safety of saxagliptin monotherapy or added to metformin in Chinese patients with type 2 diabetes mellitus: results from the 24-week, post-marketing SUNSHINE study.
Gu W; Liang L; Wang S; Wang Y; Wu Y; Tian J; Yang G; Piao C; Li Y; Yin J; Xin X; Tan X; Ning G; Wang W;
J Diabetes; 2016 Nov; 8(6):809-815. PubMed ID: 26676908
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetes.
Karyekar C; Donovan M; Allen E; Fleming D; Ravichandran S; Chen R
Postgrad Med; 2011 Jul; 123(4):63-70. PubMed ID: 21680990
[TBL] [Abstract][Full Text] [Related]
3. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial.
Jadzinsky M; Pfützner A; Paz-Pacheco E; Xu Z; Allen E; Chen R;
Diabetes Obes Metab; 2009 Jun; 11(6):611-22. PubMed ID: 19515181
[TBL] [Abstract][Full Text] [Related]
4. Impact of baseline characteristics on glycemic effects of add-on saxagliptin or acarbose to metformin therapy: Subgroup analysis of the SMART study in Chinese patients with type 2 diabetes mellitus.
Fang H; Xu F; Du J; Liang L; Li W; Shen L; Wang X; Xu C; Bian F; Mu Y
J Diabetes Investig; 2020 Jul; 11(4):896-905. PubMed ID: 32020731
[TBL] [Abstract][Full Text] [Related]
5. Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes.
Mathieu C; Ranetti AE; Li D; Ekholm E; Cook W; Hirshberg B; Chen H; Hansen L; Iqbal N
Diabetes Care; 2015 Nov; 38(11):2009-17. PubMed ID: 26246458
[TBL] [Abstract][Full Text] [Related]
6. Saxagliptin improves glycemic control by modulating postprandial glucagon and C-peptide levels in Chinese patients with type 2 diabetes.
Sjöstrand M; Iqbal N; Lu J; Hirshberg B
Diabetes Res Clin Pract; 2014 Aug; 105(2):185-91. PubMed ID: 24947443
[TBL] [Abstract][Full Text] [Related]
7. Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy.
Barnett AH; Charbonnel B; Li J; Donovan M; Fleming D; Iqbal N
Clin Drug Investig; 2013 Oct; 33(10):707-17. PubMed ID: 23949898
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety comparison of add-on therapy with liraglutide, saxagliptin and vildagliptin, all in combination with current conventional oral hypoglycemic agents therapy in poorly controlled Chinese type 2 diabetes.
Li CJ; Yu Q; Yu P; Zhang QM; Ding M; Liu XJ; Yu DM
Exp Clin Endocrinol Diabetes; 2014 Sep; 122(8):469-76. PubMed ID: 24838155
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone.
DeFronzo RA; Hissa MN; Garber AJ; Luiz Gross J; Yuyan Duan R; Ravichandran S; Chen RS;
Diabetes Care; 2009 Sep; 32(9):1649-55. PubMed ID: 19478198
[TBL] [Abstract][Full Text] [Related]
10. Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes.
Rosenstock J; Aguilar-Salinas C; Klein E; Nepal S; List J; Chen R;
Curr Med Res Opin; 2009 Oct; 25(10):2401-11. PubMed ID: 19650754
[TBL] [Abstract][Full Text] [Related]
11. A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea.
Moses RG; Kalra S; Brook D; Sockler J; Monyak J; Visvanathan J; Montanaro M; Fisher SA
Diabetes Obes Metab; 2014 May; 16(5):443-50. PubMed ID: 24205943
[TBL] [Abstract][Full Text] [Related]
12. Effects of vildagliptin versus saxagliptin on daily acute glucose fluctuations in Chinese patients with T2DM inadequately controlled with a combination of metformin and sulfonylurea.
Xiaoyan C; Jing W; Xiaochun H; Yuyu T; Shunyou D; Yingyu F
Curr Med Res Opin; 2016 Jun; 32(6):1131-6. PubMed ID: 26950829
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: a randomized controlled trial.
Yang W; Pan CY; Tou C; Zhao J; Gause-Nilsson I
Diabetes Res Clin Pract; 2011 Nov; 94(2):217-24. PubMed ID: 21871686
[TBL] [Abstract][Full Text] [Related]
14. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks.
Pfützner A; Paz-Pacheco E; Allen E; Frederich R; Chen R;
Diabetes Obes Metab; 2011 Jun; 13(6):567-76. PubMed ID: 21342412
[TBL] [Abstract][Full Text] [Related]
15. Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus.
Karyekar CS; Ravichandran S; Allen E; Fleming D; Frederich R
Clin Interv Aging; 2013; 8():419-30. PubMed ID: 23626461
[TBL] [Abstract][Full Text] [Related]
16. Adding saxagliptin to extended-release metformin vs. uptitrating metformin dosage.
Fonseca V; Zhu T; Karyekar C; Hirshberg B
Diabetes Obes Metab; 2012 Apr; 14(4):365-71. PubMed ID: 22192246
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of saxagliptin in combination with metformin as initial therapy in Chinese patients with type 2 diabetes: Results from the START study, a multicentre, randomized, double-blind, active-controlled, phase 3 trial.
Dou J; Ma J; Liu J; Wang C; Johnsson E; Yao H; Zhao J; Pan C
Diabetes Obes Metab; 2018 Mar; 20(3):590-598. PubMed ID: 28926170
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of saxagliptin compared with acarbose in Chinese patients with type 2 diabetes mellitus uncontrolled on metformin monotherapy: Results of a Phase IV open-label randomized controlled study (the SMART study).
Du J; Liang L; Fang H; Xu F; Li W; Shen L; Wang X; Xu C; Bian F; Mu Y
Diabetes Obes Metab; 2017 Nov; 19(11):1513-1520. PubMed ID: 28296055
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of saxagliptin in drug-naïve Asian patients with type 2 diabetes mellitus: a randomized controlled trial.
Pan CY; Yang W; Tou C; Gause-Nilsson I; Zhao J
Diabetes Metab Res Rev; 2012 Mar; 28(3):268-75. PubMed ID: 22081481
[TBL] [Abstract][Full Text] [Related]
20. Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials.
Cook W; Minervini G; Bryzinski B; Hirshberg B
Postgrad Med; 2014 Oct; 126(6):19-32. PubMed ID: 25414932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
